ALTIMMUNE, INC. Available-for-sale Securities, Gross Unrealized Gain
ALTIMMUNE, INC. (ALT) reported Available-for-sale Securities, Gross Unrealized Gain of -$1.05 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-14.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains · last filed 2017-03-14
- ALTIMMUNE, INC. available-for-sale securities, gross unrealized gain for the quarter ending 2016-12-31 was -$13.40K.
- ALTIMMUNE, INC. available-for-sale securities, gross unrealized gain for the quarter ending 2016-09-30 was $12.35K.
- ALTIMMUNE, INC. available-for-sale securities, gross unrealized gain for the quarter ending 2015-09-30 was $0.00.
- ALTIMMUNE, INC. available-for-sale securities, gross unrealized gain for fiscal 2016 was -$1.05K.
| Period end | Available-for-sale Securities, Gross Unrealized Gain 3 month | Available-for-sale Securities, Gross Unrealized Gain 6 month | Available-for-sale Securities, Gross Unrealized Gain 9 month | Available-for-sale Securities, Gross Unrealized Gain 12 month |
|---|---|---|---|---|
| 2016-12-31 | -$13.40K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | -$1.05K derived: sum of 2 quarters · filed 2017-03-14 | -$1.05K 10-K · filed 2017-03-14 | |
| 2016-09-30 | $12.35K 10-Q · filed 2016-11-04 | $12.35K 10-Q · filed 2016-11-04 | ||
| 2015-09-30 | $0.00 10-Q · filed 2016-11-04 | $0.00 10-Q · filed 2016-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |